BST2 antibody

Catalog No. ABIN2664562

The Rat Monoclonal anti-BST2 antibody has been validated for WB and IHC. It is suitable to detect BST2 in samples from Mouse.

Quick Overview for BST2 antibody (ABIN2664562)

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This BST2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Clone: 927

Product Details anti-BST2 Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2b kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for BST2

Target: BST2 (Bone Marrow Stromal Cell Antigen 2 (BST2))

Alternative Name: CD317

Background: CD317, known as BST2, tetherin, HM1.2 antigen, bone marrow stromal antigen 2, or PDCA-1, is type II transmembrane glycoprotein with a molecular mass of 29-33 kD. It is predominantly expressed on Type I IFN-producing cells (IPCs) in naive mice, but is up-regulated on most cell types following stimulation with type I IFNs and IFN-gamma. It is highly expressed on terminally differentiated normal plasmacytoid dendritic cells and some tumor cells, such as multiple myeloma, renal cell carcinoma, and melanoma cells. BST2 is a recently identified, IFN-induced cellular response factor that blocks release of HIV-1 and other retroviruses from infected cells. BST2 has been found to be the natural ligand of ILT7 in human model.

Pathways: Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response